MMSI:NGS-Merit Medical Systems Inc. (USD)

EQUITY | Medical Instruments & Supplies | Nasdaq Global Select

Last Closing

USD 73.78

Change

0.00 (0.00)%

Market Cap

USD 1.07B

Volume

0.28M

Analyst Target

USD 51.38
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Merit Medical Systems Inc designs, develops, manufactures and sells medical devices used in interventional and diagnostic procedures. Its products are used in thoracic surgery, interventional nephrology, vascular surgery, and oncology and pain management.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-27 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ISRG Intuitive Surgical Inc

-5.82 (-1.51%)

USD 133.13B
COO The Cooper Companies Inc.

-1.93 (-2.04%)

USD 18.82B
HOLX Hologic Inc

+0.43 (+0.57%)

USD 17.83B
RGEN Repligen Corporation

-3.47 (-2.08%)

USD 9.30B
XRAY Dentsply Sirona Inc

+0.29 (+1.04%)

USD 6.35B
AZTA Azenta Inc

-0.26 (-0.50%)

USD 2.78B
ICUI ICU Medical Inc

+1.27 (+1.19%)

USD 2.31B
STAA STAAR Surgical Company

+1.22 (+2.88%)

USD 2.31B
LMAT LeMaitre Vascular Inc

+0.08 (+0.11%)

USD 1.47B
ATRC AtriCure Inc

+0.17 (+0.76%)

USD 1.08B

ETFs Containing MMSI

PSCH Invesco S&P SmallCap Heal.. 0.00 % 0.29 %

+0.16 (+0.37%)

USD 0.20B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.87% 63% D 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.87% 63% D 47% F
Trailing 12 Months  
Capital Gain -9.24% 64% D 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.24% 64% D 40% F
Trailing 5 Years  
Capital Gain 33.18% 83% B 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 33.18% 83% B 68% D+
Average Annual (5 Year Horizon)  
Capital Gain 22.41% 73% C 81% B-
Dividend Return 22.41% 73% C 81% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 31.48% 70% C- 58% F
Risk Adjusted Return 71.19% 100% F 91% A-
Market Capitalization 1.07B 88% B+ 88% B+

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Instruments & Supplies) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 57.00 46% 22%
Price/Book Ratio 3.51 32% 30%
Price / Cash Flow Ratio 29.51 27% 9%
Price/Free Cash Flow Ratio 19.76 25% 13%
Management Effectiveness  
Return on Equity 8.05% 84% 72%
Return on Invested Capital 6.19% 80% 72%
Return on Assets 3.99% 75% 82%
Debt to Equity Ratio 68.47% 17% 33%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector